Bausch Health Companies Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BHC research report →
Range $8 – $9
Price Chart
About the company
Bausch Health Companies Inc. , together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology.
- CEO
- Thomas J. Appio
- IPO
- 1994
- Employees
- 20,300
- HQ
- Laval, QC, CA
Get TickerSpark's AI analysis on BHC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.08B
- P/E
- -3.77
- Fwd P/E
- 1.62
- PEG
- 0.01
- P/S
- 0.29
- P/B
- -2.42
- EV/EBITDA
- 8.97
- Div Yield
- 0.00%
- Gross Margin
- 72.62%
- Op Margin
- 27.97%
- Net Margin
- -7.57%
- ROE
- 58.90%
- ROIC
- 14.38%
Latest fiscal year · YoY change
- Revenue
- $10.27B+6.7%
- Gross Profit
- $7.25B+6.0%
- Op Income
- $2.19B
- Net Income
- $157.00M+441.3%
- EPS
- $0.43+430.8%
- OCF Growth
- -12.3%
- FCF Growth
- -20.4%
- 52W High
- $9.04
- 52W Low
- $4.33
- 50D MA
- $6.75
- 200D MA
- $5.85
- Beta
- 0.37
- RSI (14)
- 59
- Avg Volume
- 3.17M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Bausch Health delivered another strong quarter, topped $1 billion in quarterly adjusted EBITDA, raised full-year 2026 guidance again, and kept paying down debt while highlighting Salix and Solta momentum.· October 28, 2026
- Revenue and adjusted EBITDA both grew at a double-digit pace, with Bausch Health excluding Bausch + Lomb posting another quarter of broad-based growth.
- The company said it crossed $1 billion in quarterly adjusted EBITDA for the first time and reduced net debt by more than $500 million in the quarter.
- Salix extended its growth streak to 17 consecutive quarters, while international and Solta also contributed to the upside.
- Management raised full-year 2026 guidance again for revenue, adjusted EBITDA, and adjusted cash flow from operations.
- Q4 will face headwinds from Xifaxan-related gross-to-net accruals and channel inventory normalization tied to the Medicare price change in 2027.
Third-quarter consolidated non-GAAP revenue was $2.941 billion, up 10% reported and 8% organic year over year. Adjusted gross margin was 75%, up 32 basis points. Adjusted EBITDA was $1.305 billion, up $319 million or 32% year over year, and adjusted cash flow from operations was $782 million, up $274 million or 54%. For Bausch Health excluding Bausch + Lomb, revenue was $1.566 billion, up 12%, adjusted EBITDA was $1.022 billion, and adjusted cash flow from operations was $539 million, up $192 million year over year. Full-year 2026 guidance was raised to revenue of $5.525 billion to $5.625 billion, adjusted EBITDA of $3.225 billion to $3.275 billion, and adjusted cash flow from operations of $1.6 billion to $1.675 billion. Management said the midpoint increases were $150 million for revenue, about $190 million for adjusted EBITDA, and $200 million for adjusted cash flow from operations. They also said Q4 will be affected by a gross-to-net accrual in excess of $100 million tied to Xifaxan and by channel inventory normalization, which together will pressure Q4 growth. They cited an implied 2027 impact from the CMS/IRA-related pricing change of around $400 million to $500 million year over year.
Tom Appio framed the quarter as evidence of consistent execution, saying Bausch Health has now delivered four straight quarters of year-over-year revenue and adjusted EBITDA growth and 14 consecutive quarters of revenue and EBITDA growth across the business. He emphasized disciplined commercial execution, targeted investment, and cash generation, and said these priorities are supporting sustainable value creation. Strategically, he highlighted growth in Salix, international, and Solta, as well as the company’s pipeline and business development efforts, including larsucosterol and opportunities in hepatology, gastroenterology, dermatology, and neuroscience.
Jean-Jacques Charhon walked through the numbers, highlighting $2.941 billion of consolidated revenue, $1.305 billion of adjusted EBITDA, 75% adjusted gross margin, and $782 million of adjusted cash flow from operations. For Bausch Health excluding Bausch + Lomb, he cited $1.566 billion of revenue, $1.022 billion of adjusted EBITDA, and $539 million of adjusted cash flow from operations, and said net debt fell by $521 million in the quarter and by more than $1 billion year to date. He also said the company has $2 billion of cash on hand and is considering early redemptions of its 2027 notes, up to $100 million of open-market debt repurchases, and a $50 million share repurchase program.
Analysts focused on whether the two businesses might be more formally brought together, and Appio said nothing had changed from prior communications while reiterating confidence in Bausch + Lomb’s foundation and team. On Xifaxan, Charhon said the gross-to-net accrual tied to the 2027 Medicare price change is in excess of $100 million, and that the total net impact of the CMS-related puts and takes is roughly $400 million to $500 million year over year based on the implied 2027 guidance. Questions also centered on Solta’s organic demand, especially in Asia Pacific and North America; management pointed to softer China consumer spending, competitive pressure, a flat U.S. market, and said Solta’s Q4 will have timing-related puts and takes tied to the China distributor integration. On the Phase 3 larsucosterol program, Sadeh said they do not see a need for an interim analysis and remain on track for a 2029 approval target, subject to successful development and review.
The call showed broad-based operating momentum: Salix is still growing after 17 consecutive quarters, international businesses are positive, and Solta is benefiting from portfolio breadth and China integration. Management also raised guidance again, generated strong cash flow, and reduced debt meaningfully, which suggests the business is converting earnings growth into balance-sheet improvement.
Management repeatedly flagged a meaningful Q4 headwind from the Xifaxan Medicare price change, including a gross-to-net accrual in excess of $100 million and inventory normalization. Solta also faces near-term noise from China timing, softer consumer demand, and competition, while the company acknowledged litigation remains unresolved and the eventual CMS-related impact is still a large earnings overhang.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.6%
- Shares Outstanding
- 374.27M
- Float Shares
- 331.58M
of shares held by institutions
243 13F filers
Buy/sell ratio 0.75. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BHC, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Paulson & Co. Inc. | 73.26M | 0 |
| Goldentree Asset Management LP | 34.67M | 0 |
| Royal Bank Of Canada | 10.83M | ▼ 530.92K |
| Vanguard Group Inc | 10.68M | ▼ 1.56M |
| Vanguard Capital Management LLC | 7.44M | ▼ 20.88K |
| Acadian Asset Management LLC | 7.24M | ▲ 1.76M |
| Goldman Sachs Group Inc | 6.23M | ▲ 1.02M |
| Mfn Partners Management, LP | 6.00M | 0 |
| Sg Americas Securities, LLC | 5.54M | ▲ 5.52M |
| Hudson Bay Capital Management LP | 5.00M | 0 |
| Gendell Jeffrey L | 4.19M | ▲ 152.20K |
| Norges Bank | 3.43M | ▲ 3.43M |
Held by 15 ETFs
Biggest fund positions in BHC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Paulson John | other | 10,720 |
| Sep 30, 26 | LEUNG SANDRA | other | 5,789 |
| Sep 30, 26 | WECHSLER AMY B | other | 1,179 |
| Aug 19, 26 | Lenar Aimee J. | sell | 36,827 |
| Jul 17, 26 | Lenar Aimee J. | other | 5,260 |
| Jul 15, 26 | Lenar Aimee J. | other | 23,395 |
| Jul 14, 26 | LEE STEVEN HYOSIG | other | 3,125 |
| Jun 30, 26 | WECHSLER AMY B | other | 1,394 |
| Jun 30, 26 | Paulson John | other | 12,677 |
| Jun 30, 26 | LEUNG SANDRA | other | 6,845 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BHC coverage
Recent articles, reports, and earnings notes.
No research on BHC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BHC report →Bausch Health's Aesthetic Business, Solta Medical, Surpasses 10 Million Treatments Worldwide
prnewswire.com · Nov 19
Here's Why Bausch Health (BHC) is a Strong Momentum Stock
zacks.com · Nov 12
Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026
prnewswire.com · Nov 6
BHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan Risks
zacks.com · Nov 4
Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?
zacks.com · Nov 3
BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
zacks.com · Oct 29
Bausch Health Companies Inc. (BHC) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.